BRIEF-EU Medicines Agency recommendations for April 2017

by Reuters
Friday, 21 April 2017 17:51 GMT

April 21 (Reuters) - EU Medicines Agency -

* EU Medicines Agency recommendations for April 2017

* EU Medicines Agency recommends approval granting of a marketing authorisation for Sandoz's Rixathon Non-Hodgkin's Lymphoma (NHL), chronic lymphocytic leukaemia

* Recommends approval of Sanofi SA and Regeneron's Kevzara (Sarilumab) for treatment of rheumatoid arthritis

* Recommends approval of Biogen Spinraza drug for spinal muscular atrophy drug

* Recommends approval of Pfizer's Besponsa for treatment of acute lymphoblastic leukaemia

* Recommends approval of Biomarin Neuronal Ceroid Lipofuscinosis drug

* Recommends approval of GMP-Orphan SA's Cuprior for treatment of Wilson's disease

* Recommends approval of Almirall's Skilarence for treatment of psoriasis

* Recommends approval of Mylan S.A.S' Febuxostat Mylan for prevention and treatment of hyperuricaemia Source text - (Bengaluru Newsroom)

Our Standards: The Thomson Reuters Trust Principles.